Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02607124 · OUTCOME

Number of Patients Alive at One Year

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy · Source last updated 2020-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
1 year

Analysis population: Number of enrolled and evaluable participants

Groups in this outcome

RB+ High Grade Glioma

Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day) Ribociclib

Non-Biopsied Diffuse Instrinsic Pontine Glioma

Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day) Ribociclib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RB+ High Grade Glioma1
Non-Biopsied Diffuse Instrinsic Pontine Glioma9

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
RB+ High Grade Glioma0Not reportedNot reportedNot reportedNot reported
Non-Biopsied Diffuse Instrinsic Pontine Glioma8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        8
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      9
    units
    Participants
groups
  1. description
    Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day) Ribociclib
    id
    OG000
    title
    RB+ High Grade Glioma
  2. description
    Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day) Ribociclib
    id
    OG001
    title
    Non-Biopsied Diffuse Instrinsic Pontine Glioma
param Type
COUNT_OF_PARTICIPANTS
population Description
Number of enrolled and evaluable participants
reporting Status
POSTED
time Frame
1 year
title
Number of Patients Alive at One Year
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice